Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 411.00
+9.00 (2.24%)
Sep 16, 2026, 2:15 PM JST
Stella Pharma Revenue
Stella Pharma had revenue of 92.00M JPY in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 323.00M, down -67.44% year-over-year. In the fiscal year ending March 31, 2026, Stella Pharma had annual revenue of 323.00M, down -66.39%.
Revenue
323.00M
Revenue Growth
-67.44%
P/S Ratio
46.09
Revenue / Employee
6.87M
Employees
47
Market Cap
14.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 323.00M | -638.00M | -66.39% |
| Mar 31, 2025 | 961.00M | 692.00M | 257.25% |
| Mar 31, 2024 | 269.00M | 40.00M | 17.47% |
| Mar 31, 2023 | 229.00M | 129.00M | 129.00% |
| Mar 31, 2022 | 100.00M | -105.00M | -51.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.90B |
| ReproCELL | 2.30B |
| Immuno-Biological Laboratories | 1.08B |
| AnGes | 962.00M |
| OncoTherapy Science | 777.00M |
| Carna Biosciences | 729.00M |
| CellSeed | 161.00M |
| Kubota Pharmaceutical Holdings | 16.00M |